Deficiency of adenosine deaminase 2: a challenging differential diagnosis of polyarteritis nodosa

Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disorder that was first described in 2014. It is a monogenic disease that is caused by loss-of-function variants in the ADA2 gene. Deficiency of adenosine deaminase 2 involves small- and medium-sized vessels and its clinical presentations include polyarteritis nodosa (PAN)-like features such as livedoid rash, early-onset stroke, hypogammaglobulinemia, hematological abnormalities, and systemic inflammation. Early diagnosis and treatment of DADA2 are crucial as the clinical features could be potentially life-threatening but might be treatable. The first-line treatment of choice in DADA2 is tumor necrosis factor α inhibitors. We aimed to provide an overview of the known pathophysiology, clinical presentations, diagnosis, and treatment of DADA2. A clearer knowledge of DADA2 may help to better diagnose, manage, and improve the clinical outcome of DADA2 patients. However, further studies are required to investigate the genotype-phenotype associations and exact pathophysiology of DADA2.

[1]  D. Kastner,et al.  The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort , 2022, Frontiers in Immunology.

[2]  F. Vinchi.  Towards a Cure for Adenosine Deaminase 2 Deficiency Through Genetic Correction of Macrophage Polarization , 2021, HemaSphere.

[3]  J. Poulter,et al.  Genetics of somatic auto-inflammatory disorders. , 2021, Seminars in hematology.

[4]  L. Naldini,et al.  Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. , 2021, Blood advances.

[5]  A. Schulz,et al.  Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients , 2021, Journal of Clinical Immunology.

[6]  K. Cornetta,et al.  Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. , 2021, The New England journal of medicine.

[7]  S. Ozen,et al.  The role of vascular inflammation markers in deficiency of adenosine deaminase 2. , 2021, Seminars in arthritis and rheumatism.

[8]  Aman Sharma,et al.  Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment , 2021, Clinical Rheumatology.

[9]  O. Ohara,et al.  Detailed Analysis of Japanese Patients with Adenosine Deaminase 2 Deficiency Reveals Characteristic Elevation of Type II Interferon Signature and STAT1 Hyperactivation. , 2021, The Journal of allergy and clinical immunology.

[10]  S. Cooray,et al.  Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). , 2021, Rheumatology.

[11]  D. Kastner,et al.  Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance , 2020, Journal of Clinical Immunology.

[12]  R. Quental,et al.  Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review , 2020, Clinical Rheumatology.

[13]  Zhengping Huang,et al.  Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. , 2020, Clinical immunology.

[14]  R. Geha,et al.  Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). , 2020, The Journal of allergy and clinical immunology.

[15]  O. Kasapcopur,et al.  A 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-α , 2020, Paediatrics and international child health.

[16]  Kristen M. Gibson,et al.  Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis , 2019, Arthritis & rheumatology.

[17]  K. Jacobson,et al.  Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. , 2019, Blood.

[18]  Pui Y. Lee.  NETing the mechanism of inflammation in DADA2. , 2019, Blood.

[19]  S. Özen,et al.  A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2 , 2019, The Journal of Rheumatology.

[20]  D. Alaygut,et al.  A Child Diagnosed With Treatment-Resistant Polyarteritis Nodosa: Can the Clinical Diagnosis Be Different? , 2019, Archives of rheumatology.

[21]  D. Kastner,et al.  Treatment Strategies for Deficiency of Adenosine Deaminase 2. , 2019, The New England journal of medicine.

[22]  S. Ozen,et al.  Polyarteritis nodosa: lessons from 25 years of experience. , 2019, Clinical and experimental rheumatology.

[23]  C. Pagnoux,et al.  Diagnosis and management of ADA2 deficient polyarteritis nodosa , 2019, International journal of rheumatic diseases.

[24]  M. Hershfield,et al.  Human adenosine deaminase 2 deficiency: A multi‐faceted inborn error of immunity , 2019, Immunological reviews.

[25]  R. Geha,et al.  Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2. , 2019, The Turkish journal of pediatrics.

[26]  Pui Y. Lee.  Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2 , 2018, Front. Pediatr..

[27]  I. Meyts,et al.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment , 2018, Journal of Clinical Immunology.

[28]  Hong Jiang,et al.  Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease With Severe Consequences , 2018, Front. Immunol..

[29]  O. Sanal,et al.  ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome , 2018, Journal of Clinical Immunology.

[30]  A. Belot,et al.  [Multiple facets of ADA2 deficiency: Vasculitis, auto-inflammatory disease and immunodeficiency: A literature review of 135 cases from literature]. , 2018, La Revue de medecine interne.

[31]  M. Hershfield,et al.  Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders , 2017, Current Rheumatology Reports.

[32]  J. Dalal,et al.  Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2 , 2017, Bone Marrow Transplantation.

[33]  G. Damonte,et al.  ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study , 2017, Annals of the rheumatic diseases.

[34]  F. Penco,et al.  Monogenic polyarteritis: the lesson of ADA2 deficiency , 2016, Pediatric Rheumatology.

[35]  S. Unizony,et al.  Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. , 2016, Rheumatology.

[36]  N. Klein,et al.  Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases , 2016, Arthritis & rheumatology.

[37]  W. Flegel,et al.  The deficiency of adenosine deaminase type 2-results of therapeutic intervention , 2015, Pediatric Rheumatology.

[38]  C. Wouters,et al.  Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency , 2015, The Journal of allergy and clinical immunology.

[39]  Y. Crow,et al.  Mutations in CECR1 associated with a neutrophil signature in peripheral blood , 2014, Pediatric Rheumatology Online Journal.

[40]  T. Walsh,et al.  Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. , 2014, The New England journal of medicine.

[41]  J. Mullikin,et al.  Early-onset stroke and vasculopathy associated with mutations in ADA2. , 2014, The New England journal of medicine.

[42]  N. Glaichenhaus,et al.  Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages , 2010, Journal of leukocyte biology.

[43]  E. Lee,et al.  Clinical Features of Polyarteritis Nodosa in Korea , 2006, Journal of Korean medical science.